Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier
- PMID: 2851105
- DOI: 10.1007/BF00175787
Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier
Abstract
The neuronal noradrenaline uptake mechanism (uptake1) has been further characterized. For a number of substrates of uptake1 the half-saturating concentration (Km) and the maximal initial transport rate (Vmax) were determined. Furthermore, the dissociation constants (KD) for binding of these substrates to the desipramine binding site of the neuronal noradrenaline carrier were measured. The uptake experiments were done on rat phaeochromocytoma cells (PC12 cells), the binding experiments on purified plasma membranes of PC12 cells. The substrates differed markedly in respect of Vmax, Km, and KD. Neither Km and Vmax nor KD and Vmax were found to be correlated. However, the discrepancy between Km and KD expressed as the ratio, Km/KD, was negatively correlated with Vmax (r = -0.9315, n = 7, p less than 0.01). For the interpretation of these results a model on the basis of the steady-state assumption has been proposed for uptake1. From the mathematics of that model the following conclusions can be drawn. (1) The half-saturating substrate concentration (Km) is not identical with the dissociation constant for the binding of a substrate to the substrate recognition site (KD). (2) The discrepancy between Km and KD is expected to be negatively correlated with the maximal initial transport rate of the substrate (Vmax). The experimental results are in good agreement with the proposed model for uptake1. Especially the negative correlation between Km/KD and Vmax supports the hypothesis that desipramine inhibits uptake1 via binding to the substrate recognition site of the neuronal noradrenaline carrier.
Similar articles
-
Inhibition of neuronal noradrenaline uptake (uptake1) and desipramine binding by N-ethylmaleimide (NEM).Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337(6):633-6. doi: 10.1007/BF00175788. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3216896
-
[Methoxyflurane and ethanol do not inhibit the neuronal uptake of noradrenaline (uptake 1) at the desipramine binding site].Anaesthesist. 1990 Jul;39(7):371-4. Anaesthesist. 1990. PMID: 2386305 German.
-
Binding of 3H-desipramine to the neuronal noradrenaline carrier of rat phaeochromocytoma cells (PC-12 cells).Naunyn Schmiedebergs Arch Pharmacol. 1986 Dec;334(4):403-11. doi: 10.1007/BF00569378. Naunyn Schmiedebergs Arch Pharmacol. 1986. PMID: 3821933
-
Carrier-mediated outward transport of noradrenaline from adrenergic varicosities.Pol J Pharmacol Pharm. 1990 Nov-Dec;42(6):515-20. Pol J Pharmacol Pharm. 1990. PMID: 2103002 Review.
-
The TiPS lecture: functional aspects of the neuronal uptake of noradrenaline.Trends Pharmacol Sci. 1991 Sep;12(9):334-7. doi: 10.1016/0165-6147(91)90592-g. Trends Pharmacol Sci. 1991. PMID: 1659001 Review.
Cited by
-
Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter.Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):295-304. doi: 10.1007/BF00171060. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8878059
-
Impact of disruption of secondary binding site S2 on dopamine transporter function.J Neurochem. 2016 Sep;138(5):694-9. doi: 10.1111/jnc.13704. Epub 2016 Jul 14. J Neurochem. 2016. PMID: 27315582 Free PMC article. Review.
-
Inhibition of neuronal noradrenaline uptake (uptake1) and desipramine binding by N-ethylmaleimide (NEM).Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337(6):633-6. doi: 10.1007/BF00175788. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3216896
-
Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets.Psychopharmacology (Berl). 1990;102(2):145-55. doi: 10.1007/BF02245915. Psychopharmacology (Berl). 1990. PMID: 2274599 Review.
-
Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies.Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. doi: 10.1007/s00210-004-0949-y. Epub 2004 Jul 22. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15300361